MedTrace Logo

Evaluation of the Microbiome in Multiple Sclerosis

NCT05844826 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-15

No results posted yet for this study

Summary

To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.

Conditions

Interventions

DEVICE

SIMBA Capsule

Participants will swallow capsule

Sponsors & Collaborators

  • IGY Life Sciences

    collaborator UNKNOWN

  • Nimble Science Ltd.

    lead INDUSTRY

Principal Investigators

  • Carlos Camara-Lemarroy · University of Calgary

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-26
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05844826 on ClinicalTrials.gov